UBS lifted its price target on Endo Pharmaceuticals (NASDAQ: ENDP) Wednesday from $41 to $43 and reiterated a Buy rating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE